Chiba et al. showed that HOXB9 knockdown in pancreatic cancer cell lines elevated the sensitivity of the cells to gemcitabine and nab-paclitaxel treatment and the HOXB9 knockdown effect was rescued to the sensitivity level in control cells upon treatment with TGFβ1 recombinant [23]. Here, TGFB1 is linked to pancreatic neoplasm.